Olaparib:a new drug for hereditary ovarian cancer treatment / 药学实践杂志
Journal of Pharmaceutical Practice
;
(6): 373-375, 2015.
Article
Dans Chinois
| WPRIM
| ID: wpr-790490
ABSTRACT
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes ,and was developed by AstraZen-eca Pharmaceuticals LP .Olaparib has therapeutic potential for treating cancers associated with impaired DNA repair capabili-ties ,particularly those with deficiencies in the homologous recombination repair (HRR) pathway .Olaparib is an available ther-apy option for ovarian cancer patients with deficiencies in the BRCA 1 and BRCA2 genes .Olaparib can selectively kill cancer cells without compromising normal cells .Compared to traditional chemotherapy means ,adverse reactions are much smaller .
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of Pharmaceutical Practice
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS